top of page

Featured Publications (5)

All Selected Publications

Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria

Ito S*, Chetlapalli K*, Wang D, Potnis KC, Richmond R, Krumholz H, Lee AI, Cuker A, Goshua G.
Blood
2024
October
FEATURED
RECOGNITIONS:

Impact: Proximal complement inhibition is cost-saving for patients with suboptimal response on C5 inhibitor therapy in the United States and can be cost-saving in international jurisdictions (Penn-Yale collaboration).

PRACTICAL IMPACT:

Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia

Wang D, Ito S, Waldron C, Butt A, Zhang E, Krumholz HM, Al-Samkari H, Goshua G.
Blood Advances
2024
June
FEATURED
RECOGNITIONS:

Impact: Decreasing the need for hospital, emergency, and procedural care with the use of bevacizumab (vs no bevacizumab) improves quality-adjusted life expectancy and saves costs in the care of people living with HHT (MGH-Yale collaboration). ASH Abstract Achievement Award, Best of ASH (HTRS) (D. Wang)

PRACTICAL IMPACT:

Cost-effectiveness of rapid vs. in-house vs. send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpura

Allen C, Ito S, Butt A, Purcell A, Richmond R, Tormey CA, Krumholz HM, Cuker A, Goshua G.
Blood Advances
2024
May
FEATURED
RECOGNITIONS:

Impact: Faster adjudication of iTTP diagnosis with rapid ADAMTS13 is cost-saving for patients suspected to have iTTP, regardless of treatment regimen (Hopkins-Penn-Yale collaboration). ASH Abstract Achievement Award, Best of ASH for North America, Best of ASH (HTRS), UK TTP Registry/US TMA Selection (C. Allen)

PRACTICAL IMPACT:

Decreasing alloimmunization-specific mortality in sickle cell disease in the United States: Cost-effectiveness of a shared transfusion resource

Ito S, Pandya A, Hauser RG, Krishnamurti L, Stites E, Tormey C, Krumholz HM, Hendrickson JE, Goshua G
American Journal of Hematology
2024
April
FEATURED
RECOGNITIONS:

Impact: Supporting the mission of the 501(c)(3) Alloantibody Exchange www.alloantibody.org. 2022 ASH Press Program Selection.

PRACTICAL IMPACT:

Distributional cost-effectiveness of equity-enhancing gene therapy in sickle cell disease in the United States

Goshua G, Calhoun C, Ito S, James L, Luviano A, Krishnamurti L, Pandya A
Annals of Internal Medicine
2023
May
FEATURED
RECOGNITIONS:

Impact: For treatment funding decisions, even if gene therapy is cost-ineffective by conventional CEA standards, it is an equitable therapy per DCEA standards in the United States for patients with sickle cell disease. 2022 ASH Press Program Selection.

PRACTICAL IMPACT:
Load More
Abstract Futuristic Background

Publications

bottom of page